EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study

Lise Gether iD, Heidi Storgaard iD, Sanja Kezic iD, Ivone Jakasa iD, Bolette Hartmann iD, Kirsa Skov-Jeppesen iD, Jens J Holst iD, Anders J Pedersen iD, Julie Forman iD, Gerrit van Hall iD, Ole E Sørensen iD, Lone Skov iD und 3 weitere

Allergy · 2023-07 · 78 (7) · 1964-1979

DOI: 10.1111/all.15690 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 21.03.2023. Verfasst von Lise Gether und 14 weiteren Autor:innen. Beteiligte Einrichtung: Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Insulin Resistance, Diabetes Mellitus, Type 2, Dermatologic Agents. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Aage Bang's Foundation, LEO Pharma A/S, The Innovation Fund Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Topical corticosteroids (TCS), used to treat atopic dermatitis (AD), have been associated with type 2 diabetes and osteoporosis in epidemiological studies, possibly explained by systemic absorption.

Objectives

We examined whether intensive daily whole‐body TCS treatment over 2 weeks followed by twice weekly application for 4 weeks could elicit insulin resistance and increase bone resorption in adults with AD.

Methods

A randomized parallel‐group double‐blind double‐dummy non‐corticosteroid‐based active comparator study design was completed in Copenhagen, Denmark. Thirty‐six non‐obese, non‐diabetic adults with moderate‐to‐severe AD were randomized to whole‐body treatment with betamethasone 17‐valerate 0.1% plus a vehicle once daily or tacrolimus 0.1% twice daily after washout. Insulin sensitivity assessed by the hyperinsulinemic‐euglycemic clamp combined with tracer infusions and biomarkers of bone formation (P1NP) and resorption (CTX) were evaluated at baseline, after 2 weeks of daily treatment and after further 4 weeks of twice‐weekly maintenance treatment.

Results

AD severity improved with both treatments and systemic inflammation was reduced. After 2 weeks, we observed similar increase in peripheral insulin sensitivity with use of betamethasone ( n = 18) and tacrolimus ( n = 18). Bone resorption biomarker, CTX, was unchanged, while bone formation marker, P1NP, decreased after betamethasone treatment after both 2 and 6 weeks but remained unchanged in the tacrolimus arm.

Conclusions

Whole‐body treatment with TCS leads to systemic exposure but appears not to compromise glucose metabolism during short‐term use, which may be a result of reduced systemic inflammatory activity. The negative impact on bone formation could be regarded an adverse effect of TCS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicInsulin ResistanceDiabetes Mellitus, Type 2Dermatologic AgentsAdultHumansTacrolimusTreatment OutcomeGlucocorticoidsAdrenal Cortex HormonesDouble-Blind MethodBetamethasoneHomeostasis

Stichwörter der Autor:innen

atopic dermatitiscalcineurin inhibitorcorticosteroidosteoporosistype 2 diabetes

Substanzen

TacrolimusDermatologic AgentsGlucocorticoidsAdrenal Cortex HormonesBetamethasone

Autor:innen und Institutionen

  • Center for Clinical Metabolic Research, Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • Department of Dermatology and Allergy, Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev-Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
  • LEO Pharma A/S, Ballerup, Denmark.
  • Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
  • Department of Public and Occupational Health, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands.
  • Department of Chemistry and Biochemistry, Laboratory for Analytical Chemistry, Faculty of Food Technology and Biotechnology, University of Zagreb, Zagreb, Croatia.

ORCID-Profile: Lise Gether, Heidi Storgaard, Sanja Kezic, Ivone Jakasa, Bolette Hartmann, Kirsa Skov-Jeppesen, Jens J Holst, Anders J Pedersen, Julie Forman, Gerrit van Hall, Ole E Sørensen, Lone Skov, Mads A Røpke, Filip K Knop, Jacob Pontoppidan Thyssen

Förderung

  • Aage Bang's Foundation
  • LEO Pharma A/S
  • The Innovation Fund Denmark
  • Kongelig Hofbuntmager Aage Bangs Fond

Zitieren

APA

Gether, L., Storgaard, H., Kezic, S., Jakasa, I., Hartmann, B., Skov-Jeppesen, K., Holst, J. J., Pedersen, A. J., Forman, J., van Hall, G., Sørensen, O. E., Skov, L., Røpke, M. A., Knop, F. K., & Thyssen, J. P. (2023). Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study. Allergy, 78(7), 1964-1979. https://doi.org/10.1111/all.15690

Vancouver

Gether L, Storgaard H, Kezic S, Jakasa I, Hartmann B, Skov-Jeppesen K, et al. Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study. Allergy. 2023;78(7):1964-1979. doi:10.1111/all.15690

BibTeX
@article{Gether2023,
  author = {Gether, Lise and Storgaard, Heidi and Kezic, Sanja and Jakasa, Ivone and Hartmann, Bolette and Skov-Jeppesen, Kirsa and Holst, Jens J and Pedersen, Anders J and Forman, Julie and van Hall, Gerrit and Sørensen, Ole E and Skov, Lone and Røpke, Mads A and Knop, Filip K and Thyssen, Jacob Pontoppidan},
  title = {Effects of topical corticosteroid versus tacrolimus on insulin sensitivity and bone homeostasis in adults with atopic dermatitis—A randomized controlled study},
  journal = {Allergy},
  year = {2023},
  volume = {78},
  number = {7},
  pages = {1964--1979},
  doi = {10.1111/all.15690}
}
Kostenlos starten →